Fengabine in depression: A placebo‐controlled study of a GABA agonist

Paykel, Eugene S.; Woerkom, A. E. van; Walters, D. E.; White, William J.; Mercer, J.

doi:10.1002/hup.470060209

Cited by 11 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neither agent proved to be superior to placebo. 70 Although many antidepressants block GABAa receptors and despite advancement of a GABAA-ergic predominance hypothesis for depression,71 recent attention has focused upon the GABAb receptors.…”

Section: Combination Therapiesmentioning

confidence: 99%

Prospects for Improved Antidepressants

Broekkamp¹,

Leysen²,

Peeters³

et al. 1995

J. Med. Chem.

View full text Add to dashboard Cite

Section: Combination Therapiesmentioning

confidence: 99%

Prospects for Improved Antidepressants

Broekkamp¹,

Leysen²,

Peeters³

et al. 1995

J. Med. Chem.

View full text Add to dashboard Cite

“…Other papers (e.g. review articles, letters) in which the CID was used or cited will not be discussed in detail [12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81]. …”

Section: Resultsmentioning

confidence: 99%

The Clinical Interview for Depression: A Comprehensive Review of Studies and Clinimetric Properties

Guidi

Fava

Bech

et al. 2010

Psychother Psychosom

View full text Add to dashboard Cite

Background: A comprehensive assessment of the wide spectrum of depressive symptomatology, particularly in its subclinical forms, is lacking in standard rating scales. There is also an emerging need for instruments that can detect small differences in therapeutic studies and have good sensitivity. The purpose of this paper is to review the clinimetric characteristics of Paykel’s Clinical Interview for Depression (CID) and to examine the results of the studies in which the interview has been used. Methods: Published reports which involved the use of the CID were identified by searching the following electronic databases: Medline, PsychINFO, EMBASE, and Web of Science. A manual search of the literature was also performed. Results: The initial strategies yielded 169 published reports for potential inclusion in the review: 98 are discussed here. The CID has been used extensively in a variety of studies, including descriptive studies, classification by means of factor analysis and cluster analysis, and predictor variables of response to treatment or relapse. The CID has also been used as an outcome measure in several controlled clinical trials and follow-up studies of pharmacotherapy and psychotherapy of affective disorders. It has been shown to be valid and reliable, to discriminate depressives from controls, or different subgroups of depressed patients, and to reflect changes during the course of treatment, particularly when individual symptoms are considered. Conclusions: Evidence from these studies highlights the utility of the CID in clinical research and practice. Its clinimetric characteristics, particularly the broad evaluation of affective symptomatology and the sensitivity to change, make it an instrument of choice in therapeutic trials.

show abstract

“…The mixed GABA A and GABA B agonist, progabide, may have antidepressant properties in patients with major depression (Lloyd et al 1983). Another mixed GABA agonist, fengabine, was as effective as tricyclic antidepressants in the treatment of depression in some studies (Magni et al 1989;Nielsen et al 1990), although no more effective than placebo in another (Paykel et al 1991). Interestingly, while benzodiazepines are not thought to have striking antidepressant effects when used alone, a recent meta-analysis has demonstrated that when used in combination with antidepressant medication they increase both the efficacy and tolerability of treatment (Furukawa et al 2001).…”

Section: Changes In Gaba With Treatment Of Mood Disordermentioning

confidence: 99%

GABA and mood disorders

Taylor¹,

Bhagwagar²,

Cowen³

et al. 2003

Psychol. Med.

View full text Add to dashboard Cite

A c-aminobutyric acid (GABA)-ergic theory of mood disorders was proposed by Emrich and colleagues (1980) following observations of the efficacy of the GABAergic anticonvulsant, valproate, in the treatment of mania. Since then, increasing biochemical and pharmacological evidence from animal and human studies has supported the hypothesis that mood disorders are associated with abnormalities in brain GABA function.This evidence is now being supplemented by new information from neuroimaging studies, regarding levels of GABA and GABA receptors in mood-related brain areas of depressed patients. In addition, there have been important advances in the knowledge of the physiology of GABA neurones and their interaction with other transmitters implicated in mood regulation, in particular serotonin (5-HT). The purpose of this review is to provide a brief overview of the GABAergic abnormalities that have been reported in mood disorders in humans, and to consider how they might be reconciled with the success of 5-HT-potentiating antidepressant treatments.

show abstract

Fengabine in depression: A placebo‐controlled study of a GABA agonist

Cited by 11 publications

References 19 publications

Prospects for Improved Antidepressants

Prospects for Improved Antidepressants

The Clinical Interview for Depression: A Comprehensive Review of Studies and Clinimetric Properties

GABA and mood disorders

Contact Info

Product

Resources

About